S&P 500 Futures
(0.64%) 5 078.75 points
Dow Jones Futures
(0.40%) 38 220 points
Nasdaq Futures
(0.86%) 17 588 points
Oil
(0.66%) $79.52
Gas
(2.02%) $1.971
Gold
(-0.11%) $2 308.50
Silver
(-0.83%) $26.53
Platinum
(0.47%) $959.40
USD/EUR
(0.17%) $0.935
USD/NOK
(0.40%) $11.07
USD/GBP
(0.11%) $0.799
USD/RUB
(-1.47%) $91.89

リアルタイムの更新: Eisai Co., Ltd. [4523.T]

取引所: JPX セクター: Healthcare 産業: Drug Manufacturers—Specialty & Generic
最終更新日時2 5月 2024 @ 15:15

-0.06% ¥ 6 545.00

Live Chart Being Loaded With Signals

Commentary (2 5月 2024 @ 15:15):

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...

Stats
本日の出来高 995 400
平均出来高 1.43M
時価総額 1 878.65B
EPS ¥0 ( 2024-02-05 )
次の収益日 ( ¥41.14 ) 2024-05-13
Last Dividend ¥80.00 ( 2023-03-30 )
Next Dividend ¥0 ( N/A )
P/E 41.30
ATR14 ¥2.30 (0.04%)

ボリューム 相関

長: 0.05 (neutral)
短: -0.38 (neutral)
Signal:(42.108) Neutral

Eisai Co., Ltd. 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Eisai Co., Ltd. 相関 - 通貨/商品

The country flag -0.54
( weak negative )
The country flag -0.65
( moderate negative )
The country flag -0.34
( neutral )
The country flag -0.49
( neutral )
The country flag 0.51
( weak )
The country flag 0.68
( moderate )

Eisai Co., Ltd. 財務諸表

Annual 2022
収益: ¥744.40B
総利益: ¥566.57B (76.11 %)
EPS: ¥193.31
FY 2022
収益: ¥744.40B
総利益: ¥566.57B (76.11 %)
EPS: ¥193.31
FY 2022
収益: ¥756.23B
総利益: ¥581.40B (76.88 %)
EPS: ¥669.08
FY 2021
収益: ¥645.94B
総利益: ¥484.63B (75.03 %)
EPS: ¥146.95

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥80.00
(N/A)
¥0
(N/A)
¥80.00
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.47 - Stable (9.38%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend ¥11.50 2000-03-28
Last Dividend ¥80.00 2023-03-30
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 48 --
Total Paid Out ¥2 807.50 --
Avg. Dividend % Per Year 0.00% --
Score 3.8 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 5.47
Div. Directional Score 7.74 --
Next Divdend (Est)
(2024-07-03)
¥0 Estimate 1.26 %
Dividend Stability
0.10 Bad
Dividend Score
3.80
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
8058.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
7315.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
6564.T Ex Dividend Junior 2024-03-28 Annually 0 0.00%
5915.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
4578.T Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
3834.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
3085.T Ex Dividend Knight 2023-06-29 Semi-Annually 0 0.00%
1951.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
9507.T Ex Dividend Junior 2023-09-28 Annually 0 0.00%
8395.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06061.5008.7910.00[0 - 0.5]
returnOnAssetsTTM0.03461.2008.8510.00[0 - 0.3]
returnOnEquityTTM0.05461.500-0.504-0.756[0.1 - 1]
payoutRatioTTM1.011-1.00010.00-10.00[0 - 1]
currentRatioTTM2.380.8003.102.48[1 - 3]
quickRatioTTM1.6970.8004.723.78[0.8 - 2.5]
cashRatioTTM1.0251.5005.428.12[0.2 - 2]
debtRatioTTM0.127-1.5007.89-10.00[0 - 0.6]
interestCoverageTTM27.291.0001.0031.003[3 - 30]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM124.482.0010.0010.00[0 - 20]
debtEquityRatioTTM0.203-1.5009.19-10.00[0 - 2.5]
grossProfitMarginTTM0.7891.0000.1760.176[0.2 - 0.8]
operatingProfitMarginTTM0.08511.000-0.299-0.299[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3721.0009.049.04[0.2 - 2]
assetTurnoverTTM0.5720.8009.527.62[0.5 - 2]
Total Score10.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM41.261.0005.930[1 - 100]
returnOnEquityTTM0.05462.50-0.324-0.756[0.1 - 1.5]
freeCashFlowPerShareTTM124.482.0010.0010.00[0 - 30]
dividendYielPercentageTTM2.451.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
payoutRatioTTM1.0111.50010.00-10.00[0 - 1]
pegRatioTTM2.981.50010.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.08261.000-0.4340[0.1 - 0.5]
Total Score5.47

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。